Conexeu Sciences completes 12-month preclinical P.R.O.O.F study for CXU platform

Conexeu Sciences Inc.

12-month preclinical study met objectives for tissue restoration in cheek and 200cc-equivalent models.
CXU platform met injectability and volumizing performance benchmarks for aesthetic injectables.
GLP-1 weight-loss drug market projected to reach ~$190B by 2035, driving tissue-restoration gap to $2B by 2030.
Company plans predicate-based 510(k) submission for wound care in Q1 2027, targeting 90-day FDA review.
Patent estate spans over 40 jurisdictions including U.S., EU, Japan, and Australia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.